1.
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
by Raal, Frederick J, Prof
The Lancet (British edition), 2015, Vol.385 (9965), p.331-340
2.
Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial
by Bays, Harold
The journal of clinical endocrinology and metabolism, 2015-08, Vol.100 (8), p.3140-3148
3.
Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial
by Armitage, Jane
The Lancet (British edition), 2010, Vol.376 (9753), p.1658-1669
4.
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
by Raal, Frederick J, Prof
The Lancet (British edition), 2015, Vol.385 (9965), p.341-350
5.
Mechanism of Action of Niacin
by Kamanna, Vaijinath S., PhD
The American journal of cardiology, 2008, Vol.101 (8), p.S20-S26
6.
Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting
by Korman, Max Max
European heart journal. Cardiovascular pharmacotherapy, 2017-04-21, Vol.4 (1), p.15-22
7.
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable st...
by Stein, Evan A, Prof, Dr
The Lancet (British edition), 2012, Vol.380 (9836), p.29-36
8.
Rationale and design of the dal-OUTCOMES trial: Efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome
by Schwartz, Gregory G., MD, PhD
The American heart journal, 2009, Vol.158 (6), p.896-901.e3
9.
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LA...
by Giugliano, Robert P, Dr
The Lancet (British edition), 2012, Vol.380 (9858), p.2007-2017
10.
New LDL-Cholesterol Lowering Therapies: Pharmacology, Clinical Trials, and Relevance to Acute Coronary Syndromes
by Sahebkar, Amirhossein, PharmD, PhD
Clinical therapeutics, 2013, Vol.35 (8), p.1082-1098
11.
Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease
by Park, Hyohun
Journal of gastroenterology, 2010-07-24, Vol.46 (1), p.101-107
12.
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double...
by Raal, Frederick J, Prof
The Lancet (British edition), 2010, Vol.375 (9719), p.998-1006
13.
Management of type 2 diabetes: new and future developments in treatment
by Tahrani, Abd A, MD
The Lancet (British edition), 2011, Vol.378 (9786), p.182-197
14.
New class PCSK9 blockers stride into cholesterol market
by Sheridan, Cormac
Nature biotechnology, 2015-08, Vol.33 (8), p.785-786
15.
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial
by Fayad, Zahi A, Prof
The Lancet (British edition), 2011, Vol.378 (9802), p.1547-1559
16.
Blueberry anthocyanins at doses of 0.5 and 1 % lowered plasma cholesterol by increasing fecal excretion of acidic and neutral sterols in hamsters fed a cholesterol-enriched diet
by Liang, Yintong
European journal of nutrition, 2012-06-09, Vol.52 (3), p.869-875
17.
Reduction of blood lipid parameters by a 12-wk supplementation of aged black garlic: A randomized controlled trial
by Jung, Eun-Soo, M.S
Nutrition (Burbank, Los Angeles County, Calif.), 2014, Vol.30 (9), p.1034-1039
18.
Safety and Efficacy of Atorvastatin -Induced Very Low-Density Lipoprotein Cholesterol Levels in Patients With Coronary Heart Disease (a Post Hoc Analysis of the Treating to New Tar...
by LaRosa, John C., MD
The American journal of cardiology, 2007, Vol.100 (5), p.747-752
19.
Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study
by Kastelein, John J P, Prof
The Lancet (British edition), 2015, Vol.385 (9983), p.2153-2161
20.
Torcetrapib Induces Aldosterone and Cortisol Production by an Intracellular Calcium-Mediated Mechanism Independently of Cholesteryl Ester Transfer Protein Inhibition
by Hu, Xiao
Endocrinology (Philadelphia), 2009-05, Vol.150 (5), p.2211-2219
